About Us

The Israeli Society for the Prevention of Heart Attacks (ISPHA), a non-profit organization supervised by the Israel Ministry of Health, is located at the Neufeld Cardiac Research Institute, Sheba Medical Center Since its foundation, in the early 80′s, ISPHA has been involved in advancing medical research primarily in the area of heart disease and its prevention in Israel

ISPHA specializes in project planning, coordination and data management of clinical trials and surveys including the design and implementation of controlled clinical trials and surveys ISPHA was chosen by the Israel Heart Society to carry out its scientific research activities coordinating all 25 heart institutes and cardiac wards operating in Israel

The Center supervises the full range of clinical trials in cardiology and other medical specialties, including:

  • Primary and secondary prevention studies
  • Large-scale Israeli surveys
  • Phase 1, 2 and 3 and post marketing clinical trials
  • Data management and analysis for multi-center international surveys and studies
  • Data processing and interpretation of data gathered through research activities
  • performed by other organizations and companies

ISPHA departments and staff

  • Medical affairs
  • Administration
  • Data management
  • Computer unit
  • Statistics and Epidemiology department

Research opportunities

Taking advantage of the screening of patients for these trials, the center has compiled several large registries including thousands of patients in the areas of heart disease (coronary heart disease in particular), lipid and lipoprotein assessment and more, all available for use in future research and study Frozen sera and plasma samples collected during the screening of coronary heart disease patients for participation in the BIP study constitute the basis for investigations of novel biochemical risk factors


Ilan Goldenberg, MD

Leviev Heart Center , Sheba Medical Center

Tel Hashomer 52621 , Israel

Tel 972-3-5303068, 972-3-5344703

Fax 972-3-5305905, 972-3-5342392

E Mail: ilan.goldenberg@sheba.health.gov.il

And University of Rochester

Box 653

University of Rochester Medical Center

Rochester, NY 14642

Tel: 585-275-5391

Fax: 585-273-5283

E-mail: Ilan.Goldenberg@heart.rochester.edu









Academic Position

Professor of Medicine and Cardiology
Director , Cardiac Rehabilitation Institute and Israeli Society for the Prevention of Heart Attacks
Professor of Medicine and Cardiology, University of Rochester Medical Center


Brief Summary

Dr. Goldenberg received his medical degree from Tel Aviv University, and has completed his residency in medicine and fellowship in cardiology at Sheba Medical Center (SMC). During his cardiology training at SMC he conducted research on various topics including contrast nephropathy, smoking and sudden death, and indications for HDL raising therapy. In 2004 he joined the Heart Research Follow-up Program at the URMC and over the past 7 years was involved in clinical research that included genotype-specific risk stratification in patients with the congenital long QT syndrome, genetic risk for early onset myocardial infarction, indications for therapy with implantable devices, including the implantable cardioverter defibrillator and cardiac resybchronization therapy, and studies that involve the wearable cardioverter defibrillator.

In August 2011 he returned to Israel and  is currently the director of the cardiac rehabilitation institute and Israeli Society for the Prevention of Heart Attacks at Sheba Medical Center.

Dr. Goldenberg is the associate editor of the Inherited Arrhythmia Corner of the Annals of Noninvasive Electrocardiography, and a frequent presenter at the national and international conferences.


He has published more than 100 original articles, book chapters, and reviews.


Selected Publications:


  • Goldenberg I, Gillespie J,  Moss AJ et al, and  the executive committee of the Multicenter Automatic Defibrillator Implantation Trial-II Long-term benefit of primary prevention with an implantable cardioverter defibrillator. An extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial-II. Circulation 2010;122:1265-1271.
  • Goldenberg I, Moss AJ, Peterson DR, et al. Risk Factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 2008;29;117:2184-91.
  • Goldenberg I, Moss AJ,  , Peterson DR, et al. Long QT syndrome after age 40. Circulation 2008;117:2192-201.
  • Goldenberg I, Moss AJ, W. Hall J, et al. for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the MADIT-II Trial. Circulation. 2006;113:2810-2817.
  • Goldenberg I, Horr S, Moss AJ. Risk of life-threatening cardiac events in subjects with genotype-confirmed long-QT syndrome and a normal-resting QTc. J Am Coll Cardiol. 2010;57:51-59.
  • Goldenberg I, Vyas AK, Hall WJ; et al. MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288-296.
  • Goldenberg I, Mathew J, Moss AJ, et al. Corrected QT variability in serial electrocardiograms in long QT syndrome: the importance of the maximum corrected QT for risk stratification. J Am Coll Cardiol 2006;48:1047-1052.
  • Goldenberg I, Shechter M , Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004;25:212-218.
  • Goldenberg I,  Moss AJ, W. Hall J, et al.  Predictors of Response to Cardiac Resynchronization Therapy in MADIT-CRT. Circulation 2011 2011;124:1527-36.
  • Buber J, Mathew J, Moss AJ,  W. Hall J,  Barsheshet A,  McNitt S, Robinson JL,  Zareba W,  Ackerman MJ,  Kaufman ES, Luria D,  Eldar E, Towbin J,  Vincent M , Goldenberg I.  Risk of Recurrent Cardiac Events after Onset of Menopause in Women with Congenital Long-QT Syndrome Types 1 and 2. Circulation 2011;123:2784-2791.